Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring

Zeng, Yuchen; Wang, Anqi; Lv, Wei; Wang, Qingqing; Jiang, Shende; Pan, Xiaoguang; Wang, Fei; Yang, Huanming; Bolund, Lars; Lin, Chunhua; Han, Peng; Luo, Yonglun

doi:10.1002/ctd2.183

Cited by 5 publications

(2 citation statements)

References 156 publications

(319 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using liquid biopsies allows for the evaluation of whole tumors without being limited by their heterogeneity, which increases the amount of biopsies needed to assess the totality of the tumor. Multiple components can be measured in liquid biopsies, including the circulating tumor cells, DNA or RNA-based molecules, and extracellular vesicles, which have been one of the main focuses of cancer research [12,13].…”

Section: Bladder Cancer Overviewmentioning

confidence: 99%

The Role of miRNAs to Detect Progression, Stratify, and Predict Relevant Clinical Outcomes in Bladder Cancer

Torres-Bustamante,

Vazquez-Urrutia,

Solorzano-Ibarra

et al. 2024

IJMS

View full text Add to dashboard Cite

Bladder cancer (BC) is one of the most common types of cancer worldwide, with significant differences in survival depending on the degree of muscle and surrounding tissue invasion. For this reason, the timely detection and monitoring of the disease are important. Surveillance cystoscopy is an invasive, costly, and uncomfortable procedure to monitor BC, raising the need for new, less invasive alternatives. In this scenario, microRNAs (miRNAs) represent attractive prognostic tools given their role as gene regulators in different biological processes, tissue expression, and their ease of evaluation in liquid samples. In cancer, miRNA expression is dynamically modified depending on the tumor type and cancer staging, making them potential biomarkers. This review describes the most recent studies in the last five years exploring the utility of miRNA-based strategies to monitor progression, stratify, and predict relevant clinical outcomes of bladder cancer. Several studies have shown that multimarker miRNA models can better predict overall survival, recurrence, and progression in BC patients than traditional strategies, especially when combining miRNA expression with clinicopathological variables. Future studies should focus on validating their use in different cohorts and liquid samples.

show abstract

Section: Bladder Cancer Overviewmentioning

confidence: 99%

The Role of miRNAs to Detect Progression, Stratify, and Predict Relevant Clinical Outcomes in Bladder Cancer

Torres-Bustamante,

Vazquez-Urrutia,

Solorzano-Ibarra

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…about 80% of UC cases. 1 Therapeutic options include transurethral resection of bladder tumors and bladder perfusion chemotherapy for early-stage UBC. However, locally advanced unresectable or metastatic UC (LA/mUC) frequently presents therapeutic obstacles with limited efficacy.…”

mentioning

confidence: 99%

Human epidermal growth factor receptor 2 status in urothelial bladder carcinoma: Frequency, genomic patterns and clinical significance

Yu,

Tao,

et al. 2023

Clinical and Translational Dis

Self Cite

View full text Add to dashboard Cite

Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis

Bao,

Sui,

Wang

et al. 2024

Intl Journal of Cancer

View full text Add to dashboard Cite

Breast cancer (BC) is a complex disease with diverse manifestations, often resulting in lymph node metastasis (LNM) and impacting patient prognosis. Extrachromosomal circular DNA (eccDNA) has emerged as a key player in tumorigenesis, yet its contribution to BC LNM remains elusive. Here, we examined primary tumors and matched LNM tissues from 19 BC patients using the Circle‐Seq method. We identified a median count of 44,682 eccDNA in primary tumor tissues and 38,057 in their paired LNM tissues. Furthermore, a ladder‐like size distribution is observed in both primary tumor and LNM tissues. Meanwhile, similar repeat sequence distribution and GC content are identified from both primary tissue and LNM tissues. Finally, we found that eccDNA from both groups are flanked with palindromic trinucleotide motifs. These observations indicate that eccDNA of primary tumor and LNM tissues are from similar chromosomal origins. However, a subset of miRNA‐associated eccDNA displayed selective enrichment in metastatic lesions, such as miR‐6730 and miR‐548AA1 genes. This observation implicates the function of miRNA‐related eccDNA in the metastatic cascade. Our study uncovers the potential significance of these unique eccDNA molecules, shedding light on their role in cancer metastasis.

show abstract

Recent development of urinary biomarkers for bladder cancer diagnosis and monitoring

Cited by 5 publications

References 156 publications

The Role of miRNAs to Detect Progression, Stratify, and Predict Relevant Clinical Outcomes in Bladder Cancer

The Role of miRNAs to Detect Progression, Stratify, and Predict Relevant Clinical Outcomes in Bladder Cancer

Human epidermal growth factor receptor 2 status in urothelial bladder carcinoma: Frequency, genomic patterns and clinical significance

Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis

Contact Info

Product

Resources

About